Form 4: Crinetics Pharmaceuticals Officer Stephen F. Betz Sells 3,000 Shares

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 28, 2024, at an average price of $47.49 per share.

Summary

• On May 28, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of the company's common stock.
• The sale was executed at a volume weighted average price of $47.49 per share.
• The price range for the shares sold on that day was between $47.24 and $48.01.
• The transaction was conducted automatically under a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Betz directly owns 86,643 shares of Crinetics Pharmaceuticals.
• Marc Wilson, as attorney-in-fact, signed the Form 4 on May 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine insider transaction under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

This is a routine disclosure of an insider transaction. Insider sales can sometimes be interpreted negatively by the market, but the use of a pre-arranged Rule 10b5-1 trading plan suggests the sale was planned in advance and not based on current inside information.

Stakeholder Impact

• The sale of shares by a company officer could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates this concern.

Key Dates